Brief Description

Vedere Bio, Inc. is developing gene therapy products to restore functional vision to patients who have suffered vision loss from inherited retinal degenerations, as well as other causes of both genetic and non-genetic vision loss. Vedere aims to restore lost vision regardless of a patient's underlying genetics or their stage of disease.

Vedere was acquired by Novartis in 2020.


Ehud Isaacoff and John Flannery

Tech Category

  • Medical Therapeutics

Join the IPIRA Mailing List




Accessibility | Nondiscrimination | Privacy